DMAA Company Profile and Key Details

DMAA has shown mixed momentum, gaining 0.39% over the past week and 1.46% over the past quarter, though year-to-date performance is up 0.44%. Short-term trend indicators are bearishly aligned (SMA20 0.37%, SMA50 0.72%, SMA200 2.0%). The stock’s 14-day RSI is 66.27 (firm momentum), while the ATR of 0.02 points to tighter daily ranges. The stock remains currently trading near 52-week highs, trading 0.1% below its high and over 5.22% above its low. Average 10-day trading volume of 79.72 thousand shares is significantly above the 3-month average of 32.98 thousand, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Drugs Made In America Acquisition Corp. Ordinary Shares has 24.28 million shares outstanding. The public float is 20.97 million shares, elevated short interest at 0.45% of float. This equals 88.66 thousand shares. The short ratio is 2.31 days. Institutional investors hold 127.21% of the float. Insiders own 23.57%.

The stock is currently trading near its 52-week high $10.23 and $10.80. With a market capitalization of about $262.19 million, Drugs Made In America Acquisition Corp. Ordinary Shares is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 33.43 thousand shares, in line with its 52-week average. Headquartered in New York, NY, Drugs Made In America Acquisition Corp. Ordinary Shares operates in the Financial Services sector and the Shell Companies industry. Led by CEO Roger Bendelac, the company employs approximately 2 people and listed since January 27, 2025. Drugs Made In America Acquisition Corp. does not have significant operations.

Drugs Made In America Acquisition Corp. Ordinary Shares trades at a P/E ratio of 54.97, slightly above the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.57 suggesting the stock is closer to book value. The P/FCF stands at -810.66, also below market averages.

Drugs Made In America Acquisition Corp. Ordinary Shares (NASDAQ:DMAA) shares are flat 0.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Drugs Made In America Acquisition Corp. Ordinary Shares trading at a premium to the broader market with a P/E of 54.97. Our AI forecast model points to short-term strength (0.56% over two weeks), a medium-term rise (1.2% over three months), and a longer-term gain (192.78% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Drugs Made In America Acquisition Corp. Ordinary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.56%, with price expected at $10.86 by September 24, 2026, within a range of $10.40 to $11.35 3-Month Outlook: Projected rise of 1.2%, reaching $10.93 by December 08, 2026, with a range of $10.92 to $10.94. 1-Year Outlook: Projected gain of 192.78%, with price at $31.62 by September 10, 2027, within a range of $31.59 to $31.66.